Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study

BMC Cancer

Yong Kui Zhang¹  YanYan Hunag²  DongDong Chen²  JianYing He²  XiaoGuang Liu²  Wangyu Zhu² 

[1]Department of Cardio-Thoracic Surgery, Zhoushan Hospital of Zhejiang Province, Zhoushan, Zhejiang, 316004, 316004, China

[2]Joint Laboratory of Immunogenomics, Zhoushan Hospital-BIG/CAS, Zhoushan, Zhejiang Province, 316004, China

关键词: human lung cancer;    RT-quantitative PCR;    sera;    prognosis;    diagnosis;    miRNA;   

Others  :  1080742
DOI  :  10.1186/1471-2407-11-393

 received in 2011-06-17, accepted in 2011-09-15,  发布年份 2011

【 摘 要 】

Background

Lung cancer is the leading cause of cancer-related deaths worldwide. Early detection is considered critical for lung cancer treatment. MicroRNAs (miRNAs) have shown promise as diagnostic and prognostic indicators. This study was to identify specific miRNAs with diagnostic and prognostic value for patients with lung cancer, and to explore the correlation between expression profiles of miRNAs and patient survival.

Methods

Gene expression of members of the miR-183 family (miR-96, miR-182, and miR-183) were examined in 70 paired samples from lung cancer patients (primary cancer and non-cancerous tissues and sera), as well as 44 serum samples from normal volunteers and lung cancer cell lines by quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR). The correlation between the expression of miRNAs in tissues, sera, and patient overall survival were also examined by log-rank and Cox regression analysis.

Results

Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer.

Conclusions

Our results suggest that the expressions of miR-96, miR-182, and miR-183 in tumor and sera may be considered potential novel biomarkers for the diagnosis and prognosis of lung cancer.

【 授权许可】

   
2011 Zhu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA-Cancer J Clin 2009, 59:225-249.
• [2]Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007, 26:293-300.
• [3]Cummins J, Velculescu V: Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006, 25:6220-6227.
• [4]Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
• [5]Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
• [6]Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 2006, 103:2257-2261.
• [7]Rosell R, Wei J, Taron M: Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small cell lung cancer. Clin Lung Cancer 2009, 10:8-9.
• [8]Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
• [9]Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 2006, 9:189-198.
• [10]Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69:5776-5783.
• [11]Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T: MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70:1793-1803.
• [12]Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S, Creighton C: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:876-887.
• [13]Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol oncol 2009, 112:55-59.
• [14]Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
• [15]Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, Mamidipally C, Noronha S, Kannan S, Shirsat N: Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 2010, 6:521-529.
• [16]Lin P, Yu S, Yang P: MicroRNA in lung cancer. Br J cancer 2010, 103:1144-1148.
• [17]Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010, 126:1166-1176.
• [18]Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci 2010, 107:264-269.
• [19]Sarver AL, Li L, Subramanian S: MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010, 70:9570-9580.
• [20]Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M: Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29.
• [21]Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PloS one 2009, 4:e8003.
• [22]Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2009, 2:807.
• [23]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 2001, 25:402-408.
• [24]Liu X, Zhu W, Huang Y, Ma L, Zhou S, Wang Y, Zeng F, Zhou J, Zhang Y: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2011, in press.
• [25]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA: MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
• [26]Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DSB: Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011, 57:84-91.
• [27]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008, 105:10513-10518.
• [28]Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabr E, Croce CM, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci 2011, 108:3713-3718.
• [29]Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, Cohen L, Dan H, Zion O, Strenov Y: MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Prac 2010, 206:578-584.
• [30]Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci 2009, 106:1814-1819.
• [31]Guttilla IK, White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009, 284:23204-23216.
• [32]Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, Lam EWF: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010, 70:367-377.
• [33]Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X: miR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD 4 expression in human hepatocellular carcinoma cells. BMC cancer 2010, 10:354. BioMed Central Full Text
• [34]Abraham D, Jackson NE, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson B, Sidhu S: MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis and potential therapeutic targets. Clin Cancer Res 2011, 17:4772-4781.
• [35]Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010, 70:6015-6025.
• [36]Zhang L, Liu T, Huang Y, Liu J: microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int J Mol Med 2011, 28:381-383.
• [37]Lowery AJ, Miller N, Dwyer RM, Kerin MJ: Dysregulated miR-183 inhibits migration in breast cancer cells. BMC cancer 2010, 10:502. BioMed Central Full Text
• [38]Hyun S, Lee JH, Jin H, Nam JW, Namkoong B, Lee G, Chung J, Kim VN: Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell 2009, 139:1096-1108.
• [39]Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small cell lung cancer. J Clin Oncol 2010, 28:1721-1726.